THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC: Form 990, tax year 2010

View the entire original 990 at ProPublica ↗

Organization
THE MULTIPLE MYELOMA RESEARCH FOUNDATION INC (EIN 06-1504413)
Tax period
2010-01-01 to 2010-12-31
Filed
2011-08-05
IRS object ID
201112179349300431
Schema version
2010v3.4
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Timestamp2011-08-05T13:59:13-05:00Timestamp
Tax Period End Date2010-12-31TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

FieldValueIRS element (for citing)
Business Name Line1O'CONNOR DAVIES MUNNS & DOBBINS LLPBusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

FieldValueIRS element (for citing)
Address Line1ONE STAMFORD LANDINGAddressLine1
CitySTAMFORDCity
StateCTState
ZIP Code06902ZIPCode
FieldValueIRS element (for citing)
Return Type990ReturnType
Tax Period Begin Date2010-01-01TaxPeriodBeginDate

Filer Filer

FieldValueIRS element (for citing)
EIN061504413EIN

Name Name

FieldValueIRS element (for citing)
Business Name Line1THE MULTIPLE MYELOMA RESEARCH FOUNDATION INCBusinessNameLine1
FieldValueIRS element (for citing)
Name ControlMULTNameControl
Phone2039721250Phone

US Address USAddress

FieldValueIRS element (for citing)
Address Line1383 MAIN AVE NO 5TH FLAddressLine1
CityNORWALKCity
StateCTState
ZIP Code06851ZIPCode

Officer Officer

FieldValueIRS element (for citing)
NameKATHY GUISTIName
TitleCEO AND FOUNDERTitle
Phone2039721250Phone
Date Signed2011-07-28DateSigned
Authorize Third Party1AuthorizeThirdParty

Preparer Preparer

FieldValueIRS element (for citing)
NameROBIN STRONGName
Phone2033232400Phone
FieldValueIRS element (for citing)
Tax Year2010TaxYear
Build TS2016-02-24 21:20:13ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Name Of Principal Officer PersonKATHY GUISTINameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

FieldValueIRS element (for citing)
Address Line1383 MAIN AVE NO 5TH FLAddressLine1
CityNORWALKCity
StateCTState
ZIP Code06851ZIPCode
FieldValueIRS element (for citing)
Gross Receipts26076479GrossReceipts
Group Return For Affiliates0GroupReturnForAffiliates
Organization501c3XOrganization501c3
Web SiteWWW.THEMMRF.ORGWebSite
Type Of Organization CorporationXTypeOfOrganizationCorporation
Year Formation1997YearFormation
State Legal DomicileCTStateLegalDomicile
Activity Or Mission DescriptionTHE MISSION OF THE MMRF IS TO RELENTLESSLY PURSUE INNOVATIVE MEANS THAT ACCELERATE THE DEVELOPMENT OF NEXT-GENERATION MULTIPLE MYELOMA TREATMENTS TO EXTEND THE LIVES OF PATIENTS AND LEAD TO A CURE.ActivityOrMissionDescription
Nbr Voting Members Governing Body20NbrVotingMembersGoverningBody
Nbr Independent Voting Members19NbrIndependentVotingMembers
Total Nbr Employees26TotalNbrEmployees
Total Nbr Volunteers10TotalNbrVolunteers
Total Gross UBI0TotalGrossUBI
Net Unrelated Business Txbl Income0NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year21845537ContributionsGrantsPriorYear
Contributions Grants Current Year25650253ContributionsGrantsCurrentYear
Program Service Revenue Prior Year0ProgramServiceRevenuePriorYear
Program Service Revenue CY0ProgramServiceRevenueCY
Investment Income Prior Year68343InvestmentIncomePriorYear
Investment Income Current Year146601InvestmentIncomeCurrentYear
Other Revenue Prior Year-1183880OtherRevenuePriorYear
Other Revenue Current Year-1589455OtherRevenueCurrentYear
Total Revenue Prior Year20730000TotalRevenuePriorYear
Total Revenue Current Year24207399TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year12587247GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY13614779GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year0BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY0BenefitsPaidToMembersCY
Salaries Etc Prior Year1904518SalariesEtcPriorYear
Salaries Etc Current Year2155037SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year70000TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY151374TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year1536356TotalFundrsngExpCurrentYear
Other Expense Prior Year3502094OtherExpensePriorYear
Other Expenses Current Year4219834OtherExpensesCurrentYear
Total Expenses Prior Year18063859TotalExpensesPriorYear
Total Expenses Current Year20141024TotalExpensesCurrentYear
Revenues Less Expenses Prior Year2666141RevenuesLessExpensesPriorYear
Revenues Less Expenses CY4066375RevenuesLessExpensesCY
Total Assets BOY20585093TotalAssetsBOY
Total Assets EOY25514760TotalAssetsEOY
Total Liabilities BOY11498195TotalLiabilitiesBOY
Total Liabilities EOY12303143TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY9086898NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY13211617NetAssetsOrFundBalancesEOY
Info In Schedule O Part IIIXInfoInScheduleOPartIII
Mission DescriptionTHE MISSION OF THE MMRF IS TO RELENTLESSLY PURSUE INNOVATIVE MEANS THAT ACCELERATE THE DEVELOPMENT OF NEXT-GENERATION MULTIPLE MYELOMA TREATMENTS TO EXTEND THE LIVES OF PATIENTS AND LEAD TO A CURE.MissionDescription
Significant New Program Services1SignificantNewProgramServices
Significant Change0SignificantChange
Expense4145000Expense
Grants4145000Grants
DescriptionMULTIPLE MYELOMA RESEARCH CONSORTIUM AWARD (1 ORGANIZATION):THE MMRC INTEGRATES RESEARCH EFFORTS FROM MYELOMA RESEARCH CENTERS AND CREATES A SHARED RESEARCH ENVIRONMENT.Description

Activity2 Activity2

FieldValueIRS element (for citing)
Expense2800000Expense
Grants2800000Grants
DescriptionSENIOR RESEARCH GRANT AWARD PROGRAM (14 GRANTED IN 2010):THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SUPPORTS INVESTIGATORS WITH MORE THAN FIVE YEARS OF EXPERIENCE IN BLOOD CANCER RESEARCH. THE GOAL OF THIS INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF THERAPEUTIC APPROACHES FOR MYELOMA AND MAY INCLUDE PROPOSALS IN BASIC SCIENCE, VALIDATION, OR TRANSLATION RESEARCH.Description

Activity3 Activity3

FieldValueIRS element (for citing)
Expense2500000Expense
Grants2500000Grants
DescriptionBIOTECH INVESTMENT AWARD (5 AWARDEES IN 2010): THE MULTIPLE MYELOMA RESEARCH FOUNDATION (MMRF) SEEKS PROPOSALS FOR ITS BIOTECH INVESTMENT AWARD PROGRAM (BIA). THE GOAL OF THIS INITIATIVE IS TO DRIVE AND ACCELERATE THE DEVELOPMENT OF INNOVATIVE AND EFFECTIVE TREATMENTS FOR MYELOMA. THIS PROGRAM IS DESIGNED TO: A) PROVIDE RESOURCES NECESSARY FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES TO RAPIDLY TEST THERAPEUTICS IN MULTIPLE MYELOMA; AND B) TO FOSTER COLLABORATION WITH ACADEMIC MYELOMA EXPERTS, AS NEEDED. BIA AIMS TO REMOVE BARRIERS THAT LIMIT THE DEVELOPMENT OF NOVEL DRUGS FOR MYELOMA.Description

Activity Other ActivityOther

FieldValueIRS element (for citing)
Expense8633987Expense
Grants4169779Grants
DescriptionIN ADDITION TO THE PROGRAM EXPENSES DESCRIBED ABOVE, CORRESPONDING ACTIVITIES IN ALIGNMENT WITH THE OVERALL GOALS OF THE ORGANIZATION ARE ALSO SUPPORTED. THESE INCLUDE A PORTFOLIO OF CUTTING-EDGE RESEARCH PROGRAMS IN BASIC SCIENCE, WHICH INDENTIFIES NEW TARGETS THROUGH GENOMICS AND PROTEOMICS RESEARCH; VALIDATION STUDIES, WHICH IDENTIFY NEW COMPOUNDS AND COMBINATIONS IN RESEARCH MODELS BASED ON HIGH-PRIORITY TARGETS; AND INNOVATIVE CLINICAL TRIALS OF NOVEL AND COMBINATION TREATMENTS. ALSO, THE MMRF DEVELOPS AND IMPLEMENTS EXTENSIVE EDUCATIONAL PROGRAMMING FOR HEALTHCARE PROFESSIONALS AND FOR PATIENTS AND CAREGIVERS.Description
FieldValueIRS element (for citing)
Total Of Other Program Service Exp8633987TotalOfOtherProgramServiceExp
Total Of Other Program Service Grnt4169779TotalOfOtherProgramServiceGrnt
Total Program Service Expense18078987TotalProgramServiceExpense
Described In501 C31DescribedIn501C3
Schedule B Required1ScheduleBRequired
Political Activities0PoliticalActivities
Lobbying Activities0LobbyingActivities
Donor Advised Funds0DonorAdvisedFunds
Conservation Easements0ConservationEasements
Collections Of Art0CollectionsOfArt
Credit Counseling0CreditCounseling
Term Or Permanent Endowments0TermOrPermanentEndowments
Report Land Bldg Equip1ReportLandBldgEquip
Report Invest Oth Securities0ReportInvestOthSecurities
Report Prog Rel Invest0ReportProgRelInvest
Report Other Assets0ReportOtherAssets
Report Other Liabilities1ReportOtherLiabilities
Report Fin48 Footnote1ReportFin48Footnote
Independent Audit Financial Stmt1IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt1ConsolidatedAuditFinancialStmt
School0School
Foreign Office0ForeignOffice
Foreign Activities1ForeignActivities
More Than5000 K To Organizations1MoreThan5000KToOrganizations
More Than5000 K To Individuals0MoreThan5000KToIndividuals
Professional Fundraising1ProfessionalFundraising
Fundraising Activities1FundraisingActivities
Gaming0Gaming
Hospital0Hospital
Grants To Organizations1GrantsToOrganizations
Grants To Individuals0GrantsToIndividuals
Schedule J Required1ScheduleJRequired
Tax Exempt Bonds0TaxExemptBonds
Excess Benefit Transaction0ExcessBenefitTransaction
Prior Excess Benefit Transaction0PriorExcessBenefitTransaction
Loan To Officer Or DQP0LoanToOfficerOrDQP
Grant To Related Person0GrantToRelatedPerson
Bsnss Rltnshp With Organization0BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member0BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp0OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions1DeductibleNonCashContributions
Deductible Contributions Of Art0DeductibleContributionsOfArt
Terminated0Terminated
Partial Liquidation0PartialLiquidation
Disregarded Entity0DisregardedEntity
Related Entity1RelatedEntity
Related Org Controlled Entity0RelatedOrgControlledEntity
Transaction Related Entity0TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org0TransfersToExemptNonChrtblOrg
Activities Conducted Partnership0ActivitiesConductedPartnership
Schedule O Required1ScheduleORequired
Number Forms Transmitted With109642NumberFormsTransmittedWith1096
Number W2 G Included0NumberW2GIncluded
Compliance With Backup Witholding1ComplianceWithBackupWitholding
Number Of Employees26NumberOfEmployees
Employment Tax Returns Filed1EmploymentTaxReturnsFiled
Unrelated Business Income0UnrelatedBusinessIncome
Foreign Financial Account0ForeignFinancialAccount
Prohibited Tax Shelter Trans0ProhibitedTaxShelterTrans
Taxable Party Notification0TaxablePartyNotification
Non Deductible Contributions0NonDeductibleContributions
Quid Pro Quo Contributions1QuidProQuoContributions
Quid Pro Quo Disclosure1QuidProQuoDisclosure
Form8282 Property Disposed Of0Form8282PropertyDisposedOf
Indoor Tanning Services0IndoorTanningServices
Info In Schedule O Part VIXInfoInScheduleOPartVI
Nbr Voting Governing Body Members20NbrVotingGoverningBodyMembers
Number Independent Voting Members19NumberIndependentVotingMembers
Family Or Business Relationship1FamilyOrBusinessRelationship
Delegation Of Management Duties1DelegationOfManagementDuties
Changes To Organizing Docs0ChangesToOrganizingDocs
Material Diversion Or Misuse0MaterialDiversionOrMisuse
Members Or Stockholders0MembersOrStockholders
Election Of Board Members0ElectionOfBoardMembers
Decisions Subject To Approval0DecisionsSubjectToApproval
Minutes Of Governing Body1MinutesOfGoverningBody
Minutes Of Committees1MinutesOfCommittees
Officer Mailing Address0OfficerMailingAddress
Local Chapters0LocalChapters
Form990 Provided To Governing Body0Form990ProvidedToGoverningBody
Conflict Of Interest Policy1ConflictOfInterestPolicy
Annual Disclosure Covered Persons1AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement1RegularMonitoringEnforcement
Whistleblower Policy1WhistleblowerPolicy
Document Retention Policy1DocumentRetentionPolicy
Compensation Process CEO1CompensationProcessCEO
Compensation Process Other1CompensationProcessOther
Investment In Joint Venture0InvestmentInJointVenture
States Where Copy Of Return Is FiledCTStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledAKStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledARStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledCAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledFLStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledGAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledHIStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledKYStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMEStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMDStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMIStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMSStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNHStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNJStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNMStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNYStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledOKStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledPAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledWVStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledALStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledAZStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledCOStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledILStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledMNStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledNCStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledOHStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledRIStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledSCStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledTNStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledUTStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledVAStatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is FiledWIStatesWhereCopyOfReturnIsFiled
Own WebsiteXOwnWebsite
Upon RequestXUponRequest

The Books Are In Care Of TheBooksAreInCareOf

Name Business NameBusiness

FieldValueIRS element (for citing)
Business Name Line1JIM GRAZICKBusinessNameLine1
FieldValueIRS element (for citing)
Telephone Number2036520231TelephoneNumber

Address US AddressUS

FieldValueIRS element (for citing)
Address Line1383 MAIN AVE 5TH FLOORAddressLine1
CityNORWALKCity
StateCTState
ZIP Code06851ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (29 entries)

TitleTitleAverage Hours Per WeekAverageHoursPerWeekIndividual Trustee Or DirectorIndividualTrusteeOrDirectorReportable Comp From OrganizationReportableCompFromOrganizationReportable Comp From Related OrgsReportableCompFromRelatedOrgsOther CompensationOtherCompensationOfficerOfficerKey EmployeeKeyEmployeeHighest Compensated EmployeeHighestCompensatedEmployee
ALAN HELLER
BOARD MEMBER2.00X000
CHARLES ORTNER
BOARD MEMBER2.00X000
CHRIS MCWILTON
BOARD MEMBER2.00X000
DANA LAFORGE
CHAIRMAN2.00X000X
DONNA ZACCARO
BOARD MEMBER2.00X000
EDWARD PHILLIPS
BOARD MEMBER2.00X000
FRANK DOUGLAS PHD
BOARD MEMBER2.00X000
GENE GRISANTI
BOARD MEMBER2.00X000
GERALD MCDOUGALL
BOARD MEMBER2.00X000
KAREN ANDREWS
BOARD MEMBER2.00X000
KATHY GIUSTI
CHIEF EXECUTIVE OFFICER, PRESIDENT30.00X31141300X
KENNETH ANDERSON MD
BOARD MEMBER2.00X000
LORI TAUBER-MARCUS
BOARD MEMBER2.00X000
MERYL ZAUSNER
BOARD MEMBER2.00X000
MIKE MORTIMER
BOARD MEMBER2.00X000
ROBERT BEALL PHD
BOARD MEMBER2.00X000
STEPHEN GRAND
BOARD MEMBER2.00X000
WILLIAM MCKIERNAN
BOARD MEMBER2.00X000
DAVID PARKINSON
BOARD MEMBER2.00X000
ANTHONY KESMAN
BOARD MEMBER2.00X000
ANNE QUINN YOUNG
VP OF COMMUNICATIONS36.0013908600X
KAREN DIETZ
SECRETARY/IN-HOUSE COUNCIL32.007888300X
STEVE AMELIO
CHIEF FINANCIAL OFFICER6.40769200X
WALTER CAPONE
CHIEF OPERATING OFFICER30.0015261300X
JAMES GRAZICK
TREASURER/DIRECTOR OF FINANCE32.008032900X
LOUISE PERKINS
CHIEF SCIENTIFIC OFFICER28.0020803100X
ANNE WALKER
NATIONAL EVENTS DIRECTOR40.0013871300X
JOAN LEVY
ASS. DR. OF RESEARCH40.0013681700X
ROBERT LUCAS
VP OF DEVELOPMENT40.0020041700X
FieldValueIRS element (for citing)
Total Reportable Comp From Org1453994TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs0TotalReportableCompFrmRltdOrgs
Total Other Compensation0TotalOtherCompensation
Number Individuals GT100 K7NumberIndividualsGT100K
Formers Listed0FormersListed
Total Comp GT150 K1TotalCompGT150K
Compensation From Other Sources0CompensationFromOtherSources

Contractor Compensation ContractorCompensation (2 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1CityAddressOfContractor/AddressUS/CityStateAddressOfContractor/AddressUS/StateZIP CodeAddressOfContractor/AddressUS/ZIPCodeDescription Of ServicesDescriptionOfServicesCompensationCompensation
AOI COMMUNCIATIONS
102 PICKERING WAYEXTONPA19341MEETING AND EVENT PLANNER386499
PRICEWATERHOUSECOOPERS
2001 MARKET STREET SUITE 1700PHILADELPHIAPA19103MANAGEMENT CONSULTING281728
FieldValueIRS element (for citing)
Number Of Contractors GT100 K2NumberOfContractorsGT100K
Fundraising Events6853409FundraisingEvents
Government Grants392759GovernmentGrants
All Other Contributions18404085AllOtherContributions
Total Contributions25650253TotalContributions

Investment Income InvestmentIncome

FieldValueIRS element (for citing)
Total Revenue Column146601TotalRevenueColumn
Exclusion$146,601ExclusionAmount
FieldValueIRS element (for citing)
Gross Income Fundraising Events279625GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events6853409CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses1869080FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

FieldValueIRS element (for citing)
Total Revenue Column-1589455TotalRevenueColumn
Exclusion-$1,589,455ExclusionAmount

Total Revenue TotalRevenue

FieldValueIRS element (for citing)
Total Revenue Column24207399TotalRevenueColumn
Related Or Exempt Function Income0RelatedOrExemptFunctionIncome
Unrelated Business Revenue0UnrelatedBusinessRevenue
Exclusion-$1,442,854ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

FieldValueIRS element (for citing)
Total11764779Total
Program Services11764779ProgramServices

Foreign Grants ForeignGrants

FieldValueIRS element (for citing)
Total1850000Total
Program Services1850000ProgramServices

Comp Current Officers Directors CompCurrentOfficersDirectors

FieldValueIRS element (for citing)
Total914642Total
Program Services607358ProgramServices
Management And General190572ManagementAndGeneral
Fundraising116712Fundraising

Other Salaries And Wages OtherSalariesAndWages

FieldValueIRS element (for citing)
Total1240395Total
Program Services496021ProgramServices
Management And General165009ManagementAndGeneral
Fundraising579365Fundraising

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total151374Total
Fundraising151374Fundraising

Fees For Services Other FeesForServicesOther

FieldValueIRS element (for citing)
Total907553Total
Program Services416674ProgramServices
Management And General69902ManagementAndGeneral
Fundraising420977Fundraising

Advertising Advertising

FieldValueIRS element (for citing)
Total135092Total
Program Services121583ProgramServices
Fundraising13509Fundraising

Office Expenses OfficeExpenses

FieldValueIRS element (for citing)
Total114491Total
Program Services60885ProgramServices
Management And General18125ManagementAndGeneral
Fundraising35481Fundraising

Occupancy Occupancy

FieldValueIRS element (for citing)
Total206283Total
Program Services105617ProgramServices
Management And General34037ManagementAndGeneral
Fundraising66629Fundraising

Travel Travel

FieldValueIRS element (for citing)
Total95877Total
Program Services13916ProgramServices
Management And General5964ManagementAndGeneral
Fundraising75997Fundraising

Conferences Meetings ConferencesMeetings

FieldValueIRS element (for citing)
Total1322777Total
Program Services1321953ProgramServices
Management And General412ManagementAndGeneral
Fundraising412Fundraising

Depreciation Depletion DepreciationDepletion

FieldValueIRS element (for citing)
Total107349Total
Program Services54963ProgramServices
Management And General17713ManagementAndGeneral
Fundraising34673Fundraising

Insurance Insurance

FieldValueIRS element (for citing)
Total59019Total
Program Services47215ProgramServices
Management And General5902ManagementAndGeneral
Fundraising5902Fundraising

Other Expenses OtherExpenses (3 entries)

DescriptionDescriptionTotalTotalProgram ServicesProgramServicesManagement And GeneralManagementAndGeneralFundraisingFundraising
PATIENT AND CLINICIAN O76773176773100
CDC EXPENSE39429639429600
MISCELLANEOUS109366559961804535325

Total Functional Expenses TotalFunctionalExpenses

FieldValueIRS element (for citing)
Total20141024Total
Program Services18078987ProgramServices
Management And General525681ManagementAndGeneral
Fundraising1536356Fundraising

Cash Non Interest Bearing CashNonInterestBearing

FieldValueIRS element (for citing)
BOY500BOY
EOY500EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

FieldValueIRS element (for citing)
BOY8625596BOY
EOY12319250EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

FieldValueIRS element (for citing)
BOY7677383BOY
EOY7928343EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

FieldValueIRS element (for citing)
BOY114604BOY
EOY263243EOY
FieldValueIRS element (for citing)
Land Buildings Equipment Basis649095LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec404772LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

FieldValueIRS element (for citing)
BOY345877BOY
EOY244323EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

FieldValueIRS element (for citing)
BOY3568171BOY
EOY4567673EOY

Other Assets Total OtherAssetsTotal

FieldValueIRS element (for citing)
BOY252962BOY
EOY191428EOY

Total Assets TotalAssets

FieldValueIRS element (for citing)
BOY20585093BOY
EOY25514760EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

FieldValueIRS element (for citing)
BOY337426BOY
EOY430737EOY

Grants Payable GrantsPayable

FieldValueIRS element (for citing)
BOY10173071BOY
EOY11240911EOY

Deferred Revenue DeferredRevenue

FieldValueIRS element (for citing)
BOY7698BOY
EOY131495EOY

Other Liabilities OtherLiabilities

FieldValueIRS element (for citing)
BOY980000BOY
EOY500000EOY

Total Liabilities TotalLiabilities

FieldValueIRS element (for citing)
BOY11498195BOY
EOY12303143EOY
FieldValueIRS element (for citing)
Follow SFAS117XFollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

FieldValueIRS element (for citing)
BOY7633073BOY
EOY2866617EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

FieldValueIRS element (for citing)
BOY1453825BOY
EOY10345000EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY9086898BOY
EOY13211617EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY20585093BOY
EOY25514760EOY
FieldValueIRS element (for citing)
Info In Schedule O Part XIXInfoInScheduleOPartXI
Reconcilation Revenue Expenses4066375ReconcilationRevenueExpenses
Reconcilation Other Changes58344ReconcilationOtherChanges
Info In Schedule O Part XIIXInfoInScheduleOPartXII
Method Of Accounting AccrualXMethodOfAccountingAccrual
Accountant Compile Or Review0AccountantCompileOrReview
FS Audited1FSAudited
Audit Committee1AuditCommittee
Financial Statement BothXFinancialStatementBoth
Federal Grant Audit Required0FederalGrantAuditRequired

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Publicly Supported Org170b1 AviXPubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years14704606CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years22305441CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years22400673CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year21845537CurrentTaxYearMinus1Year
Current Tax Year25650253CurrentTaxYear
Total106906510Total

Total170 Total170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years14704606CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years22305441CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years22400673CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year21845537CurrentTaxYearMinus1Year
Current Tax Year25650253CurrentTaxYear
Total106906510Total
FieldValueIRS element (for citing)
Amounts Subst Contributors Total22672197AmountsSubstContributorsTotal
Public Support Total17084234313PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years265162CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years245441CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years113486CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year68343CurrentTaxYearMinus1Year
Current Tax Year146601CurrentTaxYear
Total839033Total
FieldValueIRS element (for citing)
Total Support107745543TotalSupport
Gross Receipts From Admissions Etc949858GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage1700.78180PublicSupportPertcentage170
Public Support Pertcent Prior Year0.78970PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170XThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

FieldValueIRS element (for citing)
Contributor NumberRESTRICTEDContributorNumber

Contributor Name Business ContributorNameBusiness

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor Address US ContributorAddressUS

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Aggregate ContributionsRESTRICTEDAggregateContributions

Schedule D IRS990ScheduleD

Equipment Equipment

FieldValueIRS element (for citing)
Other Cost Or Other Basis282943OtherCostOrOtherBasis
Depreciation209401Depreciation
Book Value73542BookValue

Other Land Buildings OtherLandBuildings

FieldValueIRS element (for citing)
Other Cost Or Other Basis366152OtherCostOrOtherBasis
Depreciation195371Depreciation
Book Value170781BookValue
FieldValueIRS element (for citing)
Total Of Book Value Land Buildings244323TotalOfBookValueLandBuildings

Other Liabilities OtherLiabilities

FieldValueIRS element (for citing)
DescriptionMMRC RESEARCH GRANT PAYABLEDescription
Amount$500,000Amount
FieldValueIRS element (for citing)
Total Of Amounts500000TotalOfAmounts
Total Revenue24207399TotalRevenue
Total Expenses20141024TotalExpenses
Excess Or Deficit For Year4066375ExcessOrDeficitForYear
Net Unrealized GL On Investments58346NetUnrealizedGLOnInvestments
Other-$2OtherAmount
Total Adjustments58344TotalAdjustments
Excess Or Deficit Per FS4124719ExcessOrDeficitPerFS
Tot Revenue Etc Audited Fincl Stmt24329799TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments58346NetUnrealizedGainsInvestments
Donated Srvc And Use Of Facilities64054DonatedSrvcAndUseOfFacilities
Revenue Not Rptd F990122400RevenueNotRptdF990
Revenue Subtotal24207399RevenueSubtotal
Revenue Not Rptd On Fin Stmt0RevenueNotRptdOnFinStmt
Total Revenue Per Form99024207399TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt20205080TotExpensesEtcAuditedFinclStmt
Donated Services Use Of Facilities64054DonatedServicesUseOfFacilities
Losses Reported2LossesReported
Expenses Not Rptd F99064056ExpensesNotRptdF990
Expenses Subtotal20141024ExpensesSubtotal
Expenses Not Rptd On Fin Stmt0ExpensesNotRptdOnFinStmt
Total Expenses Per Form99020141024TotalExpensesPerForm990

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (2 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
DESCRIPTION OF UNCERTAIN TAX POSITIONS UNDER FIN 48:PART X:THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. MANAGEMENT HAS DETERMINED THAT THE FOUNDATION HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION. THE FOUNDATION IS NO LONGER SUBJECT TO AUDITS BY THE APPLICABLE TAXING JURISDICTIONS FOR PERIOD PRIOR TO 2007.
SCHEDULE D, PAGE 4, PART XII, QUESTION 4B. AMOUNTS RECONCILING THE 990 TO THE FINANCIAL STATEMENTS TOTALING $44,120 IS THE SPECIAL EVENT IN-KIND SUPPORT DISCLOSED ON THE STATEMENT OF ACTIVITIES OF THE FINANCIAL STATEMENTS.

Schedule F IRS990ScheduleF

FieldValueIRS element (for citing)
Grant Records Maintained1GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (4 entries)

RegionRegionType Of Activities ConductedTypeOfActivitiesConductedTotal ExpendituresTotalExpenditures
NORTH AMERICAGRANTS TO RECIPIENTS LOCATED IN REGION275000
EUROPEGRANTS TO RECIPIENTS LOCATED IN REGION1100000
MIDDLE EAST AND NORTH AFRICAGRANTS TO RECIPIENTS LOCATED IN REGION200000
EAST ASIA AND THE PACIFICGRANTS TO RECIPIENTS LOCATED IN REGION275000
FieldValueIRS element (for citing)
Subtotal Number Of Employees0SubtotalNumberOfEmployees
Cont Number Of Employees0ContNumberOfEmployees
Total Number Of Employees0TotalNumberOfEmployees
Subtotal Amount Spent1850000SubtotalAmountSpent
Cont Amount Spent0ContAmountSpent
Total Amount Spent1850000TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (9 entries)

RegionRegionPurpose Of GrantPurposeOfGrantAmount Of Cash GrantAmountOfCashGrantManner Of Cash DisbursementMannerOfCashDisbursement
CALGARY, ALBERTA CANADAPAP INHIBITOR AS NOVEL THERAPEUTIC APPROACH IN MULTIPLE MYELOMA75000CHECK
AUSTRALIATHE ROLE OF SURVIVAL PROTEINS IN MULTIPLE MYELOMA DEVELOPMENT75000CHECK
NETHERLANDSTHE HUMANIZED MULTIPLE MYELOMA MOUSE MODEL200000CHECK
ISREALERYTHROPOIETIN AS AN ANTI-MULTIPLE MYELOMA IMMUNOMODULATING AGENT200000CHECK
CANADADEVELOPMENT OF THERAPEUTIC INHIBITORS FOR TREATMENT OF MULTIPLE MYELOMA.200000CHECK
ITALYAN INTEGRATED STUDY OF PROTEOSTASIS AGAINST MULTIPLE MYELOMA200000CHECK
AUSTRALIATARGETED INHIBITION OF JAK-STAT SIGNALLING TO MODIFY MM DRUG RESISTANCE200000CHECK
UNITED KINGDOMGLYCOSPHINGOLIPID INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA200000CHECK
ITALYMINIMAL RESIDUAL DISEASE TO BETTER CHARACTERIZE MULTIPLE MYELOMA RESPONSE AND DETECT EARLY RELAPSE500000CHECK
FieldValueIRS element (for citing)
Transfer To Foreign Corp0TransferToForeignCorp
Interest In Foreign Trust0InterestInForeignTrust
Own Foreign Corp0OwnForeignCorp
Passive Foreign Invest Co0PassiveForeignInvestCo
Foreign Partnership0ForeignPartnership
Boycott Countries0BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV

FieldValueIRS element (for citing)
IdentifierPROCEDURE FOR MONITORING GRANTS OUTSIDE THE U.S.:Identifier
ExplanationSCHEDULE F, PART I, LINE 2: GRANTS ARE AWARDED TO INSTITUTIONS FOR A SPECIFIC INVESTIGATORS PROJECT. INSTITUTIONS' BIOTECHNOLOGY COMPANIES OR ACADEMIC MEDICAL CENTERS' MUST HAVE A REPRESENTATIVE AGREE TO AND SIGN OFF ON THE TERMS OF A LEGALLY BINDING CONTRACT BETWEEN THE ORGANIZATION AND THE GRANTEE. THESE CONTRACTS SPECIFY THE ALLOWABLE AND NON-ALLOWABLE COSTS UNDER THE GRANT GUIDELINES AND OUTLINE CORRESPONDING REPORTING REQUIREMENTS. ALL FINANCIAL DOCUMENTS ARE REVIEWED BY ORGANIZATION'S STAFF. SCIENTIFIC REPORTS ARE SENT OUT FOR EXTERNAL PEER REVIEW TO ENSURE THEY ARE IN KEEPING WITH THE PROPOSED SPECIFIC AIMS. GRANTS THAT DEVIATE FROM THOSE AIMS MUST SUBMIT A PLAN FOR THEIR COURSE CORRECTION OR RISK TERMINATION. IF FUNDS HAVE BEEN PAID IN FULL, THE MMRF RESERVES THE RIGHT TO REQUEST A FULL ACCOUNTING AND, IF NECESSARY, REIMBURSEMENT.Explanation

Schedule G IRS990ScheduleG

FieldValueIRS element (for citing)
Mail SolicitationsXMailSolicitations
Email SolicitationsXEmailSolicitations
Phone SolicitationsXPhoneSolicitations
In Person SolicitationsXInPersonSolicitations
Solicitation Of Non Govt GrantsXSolicitationOfNonGovtGrants
Solicitation Of Govt GrantsXSolicitationOfGovtGrants
Special Fundraising EventsXSpecialFundraisingEvents
Agreement Ref Fundraising1AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation (5 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeActivityActivityFundraiser Control Of FundsFundraiserControlOfFundsGross ReceiptsGrossReceiptsAmount Retained By ContractorAmountRetainedByContractorNet To OrganizationNetToOrganization
ARRON CONSULTING
377 FIFTH AVEBROOKLYNNY11215GREENWICH GALA11876168368501839318
PAT HURLEY
205 W WACKER DRIVE 1499CHICAGOIL60606CHICAGO DINNER193306045000888060
ARRON CONSULTING
377 FIFTH AVEBROOKLYNNY11215LAUGH FOR LIFE160395018150585800
M3 DEVELOPMENT
26 WOODPACKER WAYMARLBORONJ077463.2.1 CAMPAIGN1025000-25000
STELTER
10435 NEW YORK AVEDES MOINESIA50322PLANNED GIVING1026374-26374
FieldValueIRS element (for citing)
Total Gross Receipts3413178TotalGrossReceipts
Total Retained By Contractors151374TotalRetainedByContractors
Total Net To Organization3261804TotalNetToOrganization

Events Information EventsInformation

FieldValueIRS element (for citing)
Name Of Event1CORPORATE DINNERSNameOfEvent1
Gross Receipts Event12809230GrossReceiptsEvent1
Charitable Contributions Event12595230CharitableContributionsEvent1
Gross Revenue Event1214000GrossRevenueEvent1
Rent Facility Costs Event1392841RentFacilityCostsEvent1
Entertainment Event148898EntertainmentEvent1
Other Direct Expenses Event1422534OtherDirectExpensesEvent1
Name Of Event2LAUGH PROGRAMNameOfEvent2
Gross Receipts Event2603950GrossReceiptsEvent2
Charitable Contributions Event2538325CharitableContributionsEvent2
Gross Revenue Event265625GrossRevenueEvent2
Rent Facility Costs Event270673RentFacilityCostsEvent2
Entertainment Event28550EntertainmentEvent2
Other Direct Expenses Event2107339OtherDirectExpensesEvent2
Total Number Of Other Events15TotalNumberOfOtherEvents
Gross Receipts Other Events3719854GrossReceiptsOtherEvents
Charitable Contrib Other Events3719854CharitableContribOtherEvents
Other Direct Expenses Other Events818245OtherDirectExpensesOtherEvents
Gross Receipts Total7133034GrossReceiptsTotal
Charitable Contributions Total6853409CharitableContributionsTotal
Gross Revenue Total Events279625GrossRevenueTotalEvents
Rent Facility Costs Total Events463514RentFacilityCostsTotalEvents
Entertainment Total Events57448EntertainmentTotalEvents
Other Direct Expenses Total Events1348118OtherDirectExpensesTotalEvents
Direct Expense Summary Events1869080DirectExpenseSummaryEvents
Net Income Summary-1589455NetIncomeSummary

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Records Maintained1RecordsMaintained

Recipient Table RecipientTable (30 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEIN Of RecipientEINOfRecipientAmount Of Cash GrantAmountOfCashGrantPurpose Of GrantPurposeOfGrantIRC SectionIRCSectionAddress Line2AddressUS/AddressLine2
CONSTELLATION PHARAMCEUTICALS
215 FIRST ST SUITE 200CAMBRIDGEMA02142261741721500000TARGETING HISTONE METHYLTRANSFERASES TO TREAT MULTIPLE MYELOMA
DANA FARBER CANCER INSTITUTE
44 BINEY STBOSTONMA0211504226304075000A NOVEL AURORA KINASE INHIBITOR, AT9283, AND LENALIDOMIDE IN MM501(C)(3)
DANA FARBER CANCER INSTITUTE
44 BINEY STBOSTONMA0211504226304075000MEASURING THE APOPTOTIC PRESET AS A PREDICTOR OF CHEMOSENSITIVITY501(C)(3)
DANA FARBER CANCER INSTITUTE
44 BINEY STBOSTONMA02115042263040200000INDUCTION OF MYELOMA CELL SUSCEPTIBILITY TO NK CELLS501(C)(3)
DANA FARBER CANCER INSTITUTE
44 BINEY STBOSTONMA02115042263040200000TARGETING AUTOPHAGY IN MULTIPLE MYELOMA501(C)(3)
DANA FARBER CANCER INSTITUTE
44 BINEY STBOSTONMA02115042263040200000DEVELOPMENT OF COMBINATION REGIMENS BASED ON HISTONE DEACETYLASE INHIBITORS501(C)(3)
DARTMOUTH MEDICAL SCHOOL NORRIS COTTON CANCER CENTER
11 ROPE FERRY RD 6210HANOVERNH03755020222111200000MOLECULAR MECHANISMS OF INTRINSIC RESISTANCE OF MYELOMA CELLS TO BORTEZOMIB
EPIZYME
840 MEMORIAL DRIVECAMBRIDGEMA02139261349956500000DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF WH SC1 (MMSET) FOR THE TREATMENT OF T (4;14) MYELOMA PATIENTS
H LEE MOFFITT CANCER CENTER
12902 MAGNOLIA DRIVETAMPAFL33612590965591200000ROLE OF CALCIUM IN MEDIATING C-HYD1 AND HYD1 INDUCED CELL DEATH IN MM501(C)(3)
H LEE MOFFITT CANCER CENTER
12902 MAGNOLIA DRIVETAMPAFL33612592451713250000REGULATION OF MULTIPLE MYELOMA BY MYELOID CELLS501(C)(3)
INSTITUTION HEALTH RESEARCH INC ROSWELL PARK CANCER INSTITUTE DIVISION
ELM AND CARLTON STREET BLSC L5-318BBUFFALONY14263141402155250000UNDERSTANDING THE MYELOID MICROENVIRONMENT IN MULTIPLE MYELOMAL5-318B
INTELLIKINE
10931 NORTH TORREY PINES ROAD SUITELA JOLLACA92037208914077500000DEVELOPMENT OF INK128, A SELECTIVE TORC1/2 INHIBITOR IN MULTIPLE MYELOMA103
JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
CRB245 1650 ORLEANS STREETBALTIMOREMD21287520595110500000QUANTIFICATION OF CIRCULATING TUMOR SPECIFIC DNA IN MULTIPLE MYELOMA
KARYOPHARM
15 BONTEMPO ROADNEWTONMA02459500000SMALL MOLECULE CRM1 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
MAYO CLINICMAYO CLINIC COLLEGE OF MEDICINE
PO BOX 4006ROCHESTERMN55905416011702200000EXPLORING THE ROLE OF UCH-L1 IN THE PATHOGENESIS OF MYELOMA
MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE
1120 15TH STREETAUGUSTAGA3091258141820275000THE NFKB2-IL10 PATHWAY IN MULTIPLE MYELOMA PATHOGENESIS
MICHIGAN STATE UNIVERSITY
301 ADMINISTRATION BUILDINGEAST LANSINGMI48824386005984200000DEVELOPMENT OF ALLOSTERIC PROTEASOME INHIBITORS FOR THE TREATMENT OF MM
NORTHWESTERN UNIVERSITY -
303 E SUPERIOR STREET LURIE 5-123CHICAGOIL60611362167817250000ELUCIDATION OF THERAPEUTIC TARGETS IN MMSET-ASSOCIATED MYELOMA
SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
10901 NORTH TORREY PINES ROADLA JOLLACA9203746045037875000TARGETING UBC13 FOR MULTIPLE MYELOMA TREATMENT
STANFORD UNIVERSITY
875 BLAKE WILBUR DRIVE ROOM G-211STANFORDCA94305941156365200000TARGETING THE UNFOLDED PROTEIN RESPONSE FOR CANCER THERAPY
TGEN
445 NORTH 5TH STREET SUITE 423PHOENIXAZ85004753065445250000CONSEQUENCES OF KDM6A/UTX LOSS IN MULTIPLE MYELOMA
THE VA PITTSBURG HEALTHCARE SYSTEM
151-U-2W-143 UNIVERSITY DRIVE CPITTSBURGHPA15240250965591250000THE ROLE OF XBP1S IN MULTIPLE MYELOMA MICROENVIRONMENT
TRAGARA
10955 VISTA SORRENTO PARKWAY SUITESAN DIEGOCA92130320162504500000DEVELOPMENT OF TG02, A MULTI-KINASE INHIBITOR IN MULTIPLE MYELOMA120
UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES
4301 WEST MARKHAMLITTLE ROCKAK72205716046242250000IDENTIFICATION OF MOLECULAR TARGETS IN MYELOMA MICROENVIRONMENTS
UNIVERSITY OF CALIFORNIA LOS ANGELES
11000 KINROSS STREET SUITE 102 3RDLOS ANGELESCA90095956006143200000TARGETING TYPE 1 IFN AND TRAIL TO MM USING ANTI-CD138 FUSION PROTEINSFLOOR
VIRGINIA COMMONWEALTH UNIVERSITY
BOX 843039 730 EAST BROAD STRICHMONDVA23298546000545200000HDAC INHIBITORS AND BH3 MIMETICS IN RESISTANT/REFRACTORY MULTIPLE MYELOMA
THE UNIVERSITY OF TEXAS MD ANDERSON CANCE
7455 FANNINHOUSTONTX7705474600111875000MACROPHAGES PROTECT MYELOMA CELLS FROM CHEMOTHERAPY DRUG-INDUCED APOPTOSIS
UT M D ANDERSON CANCER CENTER
7455 FANNINHOUSTONTX77054746001118200000MECHANISMS OF LENALIDOMIDE RESISTANCE
UNIVERSITY OF UTAH SCHOOL OF MEDICINE
201 S PRESIDENTS CIRCLE ROOM 406SALT LAKE CITYUT84132876000525200000NOVEL TREATMENT APPROACHES TO TARGET THE RARA2 POSITIVE MYELOMA CELL
MULTIPLE MYELOMA RESEARCH CONSORTIUM
383 MAIN AVENUENORWALKCT068518106407754145000CLINICAL DRUG FUNDING501(C)(3)
FieldValueIRS element (for citing)
Total Nbr Of Other Organizations8TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

FieldValueIRS element (for citing)
IdentifierPROCEDURE FOR MONITORING GRANTS IN THE U.S.:Identifier
Return ReferencePART I, LINE 2:ReturnReference
ExplanationSCHEDULE I, PART I, LINE 2: GRANTS ARE AWARDED TO INDIVIDUAL INVESTIGATORS ON BEHALF OF THEIR INSTITUTIONS. INSTITUTIONS' BIOTECHNOLOGY COMPANIES OR ACADEMIC MEDICAL CENTERS' MUST HAVE A REPRESENTATIVE AGREE TO AND SIGN OFF ON THE TERMS OF A LEGALLY BINDING CONTRACT BETWEEN THE ORGANIZATION AND THE GRANTEE. THESE CONTRACTS SPECIFY THE ALLOWABLE AND NON-ALLOWABLE COSTS UNDER THE GRANT GUIDELINES AND OUTLINE CORRESPONDING REPORTING REQUIREMENTS. ALL FINANCIAL DOCUMENTS ARE REVIEWED BY ORGANIZATION'S STAFF. SCIENTIFIC REPORTS ARE SENT OUT FOR EXTERNAL PEER REVIEW TO ENSURE THEY ARE IN KEEPING WITH THE PROPOSED SPECIFIC AIMS. GRANTS THAT DEVIATE FROM THOSE AIMS MUST SUBMIT A PLAN FOR THEIR COURSE CORRECTION OR RISK TERMINATION. IF FUNDS HAVE BEEN PAID IN FULL, THE MMRF RESERVES THE RIGHT TO REQUEST A FULL ACCOUNTING AND, IF NECESSARY, REIMBURSEMENT.Explanation

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
Compensation CommitteeXCompensationCommittee
Form990 Of Other OrganizationsXForm990OfOtherOrganizations
Compensation SurveyXCompensationSurvey
Board Or Committee ApprovalXBoardOrCommitteeApproval
Severance Payment0SeverancePayment
Supplemental Nonqual Retire Plan0SupplementalNonqualRetirePlan
Equity Based Comp Arrangement0EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org0CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs0CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org0CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs0CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments0AnyNonFixedPayments
Initial Contract Exception0InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (4 entries)

Base Compensation Filing OrgBaseCompensationFilingOrgComp Based On Related OrgsCompBasedOnRelatedOrgsBonus Filing OrgBonusFilingOrgBonus Related OrgsBonusRelatedOrgsOther Compensation Filing OrgOtherCompensationFilingOrgOther Compensation Related OrgsOtherCompensationRelatedOrgsDeferred Comp Filing OrgDeferredCompFilingOrgDeferred Comp Related OrgsDeferredCompRelatedOrgsNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgNontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgsTotal Compensation Filing OrgTotalCompensationFilingOrgTotal Compensation Related OrgsTotalCompensationRelatedOrgsComp Report Prior990 Filing OrgCompReportPrior990FilingOrgComp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
KATHY GIUSTI
2864130250000000000311413000
WALTER CAPONE
152613000000000152613000
LOUISE PERKINS
1930310150000000000208031000
ROBERT LUCAS
200417000000000200417000

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTraded

FieldValueIRS element (for citing)
Non Cash CheckboxXNonCashCheckbox
Number Of Contributions24NumberOfContributions
Noncash Contribs Rptd F990482600NoncashContribsRptdF990
Method Of Determining RevenuesFMV AT DAY OF RECEIPT/SAMethodOfDeterminingRevenues
FieldValueIRS element (for citing)
Any Property That Must Be Held0AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts0ReviewProcessUnusualNCGifts
Third Parties Used0ThirdPartiesUsed

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (9 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
NEW PROGRAM SERVICESFORM 990, PART III, LINE 2THE MULTIPLE MYELOMA RESEARCH FOUNDATION, (THE "MMRF") INTENDS TO SPONSOR A MULTI-YEAR PERSONALIZED MEDICINE RESEARCH INITIATIVE IN MULTIPLE MYELOMA. IT BEGAN CERTAIN PROCESSES IN TAX YEAR 2010 IN CONTEMPLATION OF SUCH INITIATIVE AND INTENDS TO START SUCH INITIATIVE BEGINNING IN TAX YEAR 2011. THIS IS A NEW ACTIVITY FOR THE MMRF AS IT WILL BE TAKING ON THE RESPONSIBILITIES OF A SPONSOR OF RESEARCH (E.G., INITIATION, MANAGEMENT, AND/OR FINANCING OF THE RESEARCH) RATHER THAN SIMPLY FUNDING SUCH RESEARCH SPONSORED BY A THIRD PARTY, AS IT HAS DONE PREVIOUSLY. THEREFORE, MMRF IS REPORTING THIS ACTIVITY TO THE IRS AS A CHANGE IN ITS ACTIVITIES PURSUANT TO SECTION III QUESTION 2 OF THIS FORM 990. PURSUANT TO THE MMRF'S CERTIFICATE OF INCORPORATION, ONE OF ITS PURPOSES IS TO "SUPPORT AND PROMOTE IMPROVED TREATMENT AND DEVELOPMENT OF A CURE FOR MULTIPLE MYELOMA... [N]OTWITHSTANDING ANY OTHER PROVISION OF THIS CERTIFICATE OF INCORPORATION, THE OBJECTS AND PURPOSES OF THE CORPORATION SHALL BE EXCLUSIVELY CHARITABLE, SCIENTIFIC AND EDUCATIONAL WITHIN THE MEANING OF CODE SECTION 501(C)(3)." TO MEET THIS PURPOSE, THE MMRF INTENDS TO SPONSOR SCIENTIFIC RESEARCH CARRIED ON IN THE PUBLIC INTEREST TO DISCOVER A CURE FOR MULTIPLE MYELOMA. MMRF INTENDS TO SPONSOR A PERSONALIZED MEDICINE INITIATIVE IN WHICH 1000 OR MORE NEWLY DIAGNOSED PATIENTS WILL BE ENROLLED THROUGH SEVERAL SITES (I.E., HOSPITALS, ACADEMIC MEDICAL CENTERS AND OTHER COMMUNITY HEALTH CENTERS) ACROSS THE COUNTRY. NO EXPERIMENTAL DRUG WILL BE USED IN THE STUDY. RATHER BLOOD AND BONE MARROW SAMPLES WILL BE TAKEN FROM THE PATIENTS PERIODICALLY OVER THE COURSE OF THEIR TREATMENT. THE STANDARD OF CARE (I.E., DRUGS AND TREATMENT) FOR EACH PATIENT WILL BE DETERMINED BY SUCH PATIENT'S PERSONAL PHYSICIAN. THE TISSUES SAMPLES COLLECTED WILL BE PLACED IN A BIOBANK. AN UNRELATED, THIRD PARTY, NOT-FOR-PROFIT BIOMEDICAL RESEARCH INSTITUTE WOULD THEN PERFORM LABORATORY TESTS ON A PORTION OF EACH OF THE SAMPLES RESULTING IN GENOMIC DATA ABOUT EACH PATIENT. THE PURPOSE OF THE RESEARCH STUDY AS SET FORTH IN THE RESEARCH STUDY PROTOCOL IS AS FOLLOWS: "THE OBJECTIVE OF THIS LONGITUDINAL STUDY IS TO IDENTIFY PATIENT SUBGROUPS AND PHENOTYPES DEFINED BY MOLECULAR PROFILING AND CLINICAL FEATURES. THESE PROFILES WILL ENABLE A BETTER UNDERSTANDING OF MECHANISMS OF DISEASE, DRUG RESPONSE AND PATIENT RELAPSE. ULTIMATELY THE STUDY IS INTENDED TO DRIVE SUCCESSFUL DRUG DEVELOPMENT AND PATIENT CARE IN MULTIPLE MYELOMA." BASICALLY, A PERSONALIZED MEDICINE APPROACH LOOKS AT AN INDIVIDUALS GENETIC MAKE UP, ALLOWING PHYSICIANS TO GIVE THE RIGHT DRUG, AT THE RIGHT DOSE, TO THE RIGHT PATIENT, AT THE RIGHT TIME BASED ON THE PATIENT'S GENETIC INFORMATION. IN OTHER WORDS, THE ULTIMATE GOAL OF THE RESEARCH STUDY IS TO COME UP WITH A STANDARD OF CARE MODEL FOR MULTIPLE MYELOMA BASED ON A PATIENT'S GENOMIC DATA. ONCE A CERTAIN NUMBER (E.G., 50) OF PATIENTS' INFORMATION HAS BEEN COLLECTED AND THE GENOMIC DATA PRODUCED FROM THE LABORATORY TESTS CONDUCTED BY THE THIRD PARTY, THE GENOMIC DATA AND THE CLINICAL DATA COLLECTED ON EACH PATIENT, WILL BE PLACED INTO ONE LARGE DATABASE (I.E., THAT CONTAINS BOTH GENOMIC AND CLINICAL DATA) (THE "PATIENT DATA REPOSITORY"). THE PATIENT DATA REPOSITORY WILL THEN BE ACCESSIBLE VIA THE INTERNET TO RESEARCHERS. EACH TIME A NEW MILESTONE NUMBER OF PATIENTS' SAMPLES HAVE BEEN ANALYZED AND GENOMIC INFORMATION DERIVED (E.G., 50, 100, 150, 200 ETC.), SUCH INFORMATION, ALONG WITH THE CLINICAL DATA OF THE RELEVANT PATIENTS, WILL BE POSTED TO THE PATIENT DATA REPOSITORY AND ACCESS GRANTED TO RESEARCHERS. ACCESS TO INFORMATION POSTED TO THE PATIENT DATA REPOSITORY WILL OCCUR AS FOLLOWS: AFTER ANY POSTING OF INFORMATION TO THE PATIENT DATA REPOSITORY, THE MMRF, CERTAIN PRINCIPAL INVESTIGATORS IN MULTIPLE MYELOMA RESEARCH FROM LEADING ACADEMIC MEDICAL CENTERS, CERTAIN SITES WHICH HAVE ENROLLED PATIENTS INTO THE RESEARCH STUDY (E.G., HIGH ENROLLING SITES), A NOT-FOR-PROFIT BIOMEDICAL RESEARCH INSTITUTE WHICH IS A LEADER IN GENOMIC RESEARCH, AND CERTAIN PHARMACEUTICAL AND BIOTECH COMPANIES WILL HAVE ACCESS TO THE INFORMATION FOR THE FIRST NINE MONTHS AFTER EACH POSTING OF INFORMATION. EACH WILL HAVE THE RIGHT TO PUBLISH THEIR FINDINGS (I.E., IN SCIENTIFIC JOURNALS, TREATISE, ETC.) STARTING 9 MONTH AFTER EACH POSTING. AFTER THE FIRST 9 MONTHS FOLLOWING ANY POSTING OF INFORMATION, ANY RESEARCHERS AND ENROLLING SITES INVOLVED IN THE RESEARCH STUDY THAT DID NOT YET HAVE ACCESS TO THE PATIENT DATA REPOSITORY WILL HAVE ACCESS AND BE ABLE TO PUBLISH THEIR FINDINGS. AT THE END OF THE 12TH MONTH FOLLOWING ANY POSTING, THE INFORMATION CONTAINED IN SUCH POSTING WILL BE AVAILABLE TO THE INTERESTED PUBLIC FOR RESEARCH, EDUCATION AND PUBLICATION. FUNDING FOR THE PERSONALIZED MEDICINE INITIATIVE WILL BE DERIVED PRIMARILY (>60%) FROM PRIVATE DONATIONS. SUPPLEMENTAL FUNDING WILL ALSO BE FROM SEVERAL PHARMACEUTICAL AND BIOTECH COMPANIES. THESE COMPANIES WILL NOT HAVE ANY DECISION-MAKING AUTHORITY OVER THE PROTOCOL DESIGN, OVER WHO CAN ACCESS INFORMATION POSTED TO THE PATIENT DATA REPOSITORY, OVER THE CONTENT OF INFORMATION POSTED TO THE PATIENT DATA REPOSITORY, OR OVER WHO CAN ACCESS PATIENT TISSUE. THE SELECTION OF ENROLLING SITES IS IN THE SOLE DISCRETION OF THE MMRF. ALL SCIENTIFIC DECISIONS WILL BE MADE BY A SCIENTIFIC ADVISORY BOARD COMPOSED SOLELY OF NON-INDUSTRY SCIENTISTS AND RESEARCHERS. TISSUE SAMPLES FROM THE PATIENTS IN THE RESEARCH STUDY WILL BE AVAILABLE TO THE ENTITIES AND INDIVIDUALS WHO HAVE HAD ACCESS TO THE PATIENT DATA REPOSITORY, WITH CONSIDERATION GOING TO THE ENTITIES AND RESEARCHERS WHO PARTICIPATED DIRECTLY IN THE RESEARCH STUDY AND WHO CAN MOST EFFICIENTLY AND EFFECTIVELY USE THE SAMPLES IN CONJUNCTION WITH THE INFORMATION POSTED IN THE PATIENT DATA REPOSITORY TO FURTHER A CURE FOR MULTIPLE MYELOMA.
FORM 990, PART VI, SECTION A, LINE 2KATHY GIUSTI, CEO AND KAREN ANDREWS, CO-FOUNDER AND BOD MEMBER ARE SISTERS.
FORM 990, PART VI, SECTION A, LINE 3JUDITH FINLEY PROVIDED HUMAN RESOURCE SERVICES AND REPORTED DIRECTLY TO THE CEO. KATHY GUISTI.
FORM 990, PART VI, SECTION B, LINE 11THE 990 FORM IS REVIEWED INTERNALLY BY THE EXECUTIVE MANAGEMENT WITH NOTIFICATION AND COPIES OF THE 990 SENT TO MEMBERS OF THE BOARD UPON FILING.
FORM 990, PART VI, SECTION B, LINE 12CDUTY TO DISCLOSE A POTENTIAL CONFLICT OF INTEREST. ANY INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER FINANCIAL INTEREST TO THE BOARD OR CONFLICTS COMMITTEE AND MUST BE GIVEN THE OPPORTUNITY TO DISCLOSE ALL MATERIAL FACTS TO THE BOARD, MEMBERS OF THE CONFLICTS COMMITTEE AND ALL MEMBERS OF ANY COMMITTEE CONSIDERING THE PROPOSED CONTRACT OR TRANSACTION. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS. AFTER DISCLOSURE OF THE FINANCIAL INTEREST AND ALL MATERIAL FACTS, AND AFTER ANY DISCUSSION WITH THE INTERESTED PERSON, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR CONFLICTS COMMITTEE MEETING WHILE THE DETERMINATION OF A CONFLICT OF INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD OR CONFLICT COMMITTEE MEMBERS, AS APPLICABLE, SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST. I. AN INTERESTED PERSON MAY MAKE A PRESENTATION AT THE BOARD OR CONFLICTS COMMITTEE MEETING, BUT AFTER SUCH PRESENTATION, HE OR SHE SHALL LEAVE THE MEETING DURING THE DISCUSSION OF, AND THE VOTE ON, THE CONTRACT OR TRANSACTION THAT RESULT IN THE CONFLICT OF INTEREST. II. THE CHAIR OF THE BOARD OR CHAIRPERSON OF THE CONFLICTS COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR APPOINT OR ESTABLISH AN ADVISORY COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED CONTRACT OR TRANSACTION. AFTER EXERCISING DUE DILIGENCE, THE BOARD OR THE CONFLICTS COMMITTEE SHALL TAKE ALL REASONABLE STEPS TO DETERMINE WHETHER THE MMRF CAN OBTAIN A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. IF A MORE ADVANTAGEOUS CONTRACT OR TRANSACTION IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR CONFLICT COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE, BUT NOT LESS THAN TWO, OF THE DISINTERESTED DIRECTORS OR MEMBERS THEREOF WHETHER THE CONTRACT OR TRANSACTION IS IN THE MMRFS BEST INTEREST AND IS FAIR AND REASONABLE TO THE MMRF; PROVIDED, HOWEVER, IF SUCH CONTRACT OR TRANSACTION IS APPROVED BY DISINTERESTED DIRECTORS WHO DO NOT SATISFY A QUORUM OR VOTING REQUIREMENT APPLICABLE TO THE AUTHORIZATION OF THE ACTION BY REASON OF THE MMRFS CERTIFICATE OF INCORPORATION, BYLAWS OR A PROVISION OF LAW, THE ACTION MUST BE INDEPENDENTLY APPROVED BY SUCH INTERESTED AND DISINTERESTED DIRECTORS AS SATISFY THE APPLICABLE QUORUM OR VOTING REQUIREMENT. VIOLATION OF THE CONFLICTS OF INTEREST POLICY III. IF THE BOARD OR CONFLICTS COMMITTEE HAS REASONABLE CAUSE TO BELIEVE THAT A DIRECTOR, OFFICER OR COMMITTEE MEMBER HAS FAILED TO DISCLOSE ACTUAL OR POSSIBLE CONFLICTS OF INTEREST, IT SHALL INFORM SUCH PERSON OF THE BASIS FOR SUCH BELIEF AND AFFORD SUCH PERSON AN OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. IF, AFTER HEARING THE RESPONSE OF THE DIRECTOR, OFFICER OR COMMITTEE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE BOARD OR CONFLICTS COMMITTEE DETERMINES THAT SUCH PERSON HAS IN FACT FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, THE BOARD OR CONFLICTS COMMITTEE, AS APPLICABLE, SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION.
FORM 990, PART VI, SECTION B, LINE 15PROCESS FOR DETERMINING COMPENSATION OF: A. CEO, EXECUTIVE DIRECTOR OR TOP MANAGEMENT OFFICIAL - THE HUMAN RESOURCES COMMITTEE SHALL BE RESPONSIBLE FOR (A) ASSISTING THE BOARD IN ENSURING THAT THE HUMAN RESOURCES AND COMPENSATION POLICES OF THE CORPORATION ARE (I) IN ACCORDANCE WITH ALL LAWS AND REGULATION; (II) WITHIN THE BUDGET APPROVED BY THE BOARD; AND (III) CONDUCIVE TO INDIVIDUAL AND GROUP PRODUCTIVITY AND MORALE; (B) PROVIDING GUIDANCE REGARDING THE CORPORATION'S PERSONNEL POLICIES AND THEIR ADMINISTRATION; (C) KEEPING THE EXECUTIVE COMMITTEE INFORMED OF ANY MATTERS WITH RESPECT TO THE CORPORATIONS' HUMAN RESOURCES, PERSONNEL AND COMPENSATION POLICIES THAT REQUIRE THE ATTENTION OF THE BOARD; (D) REVIEWING THE CORPORATION'S EMPLOYMENT AND PERSONNEL POLICIES AND MONITORING THEIR IMPLEMENTATION; (E) HAVING OVERSIGHT RESPONSIBILITY TO ENSURE THAT THERE ARE WELL-DEFINED PERSONNEL PROCEDURES IN KEEPING WITH BEST STANDARDS AND THAT ALL EMPLOYEES ARE INFORMED IN WRITING ABOUT PERSONNEL POLICIES AND PROCEDURE; (F) REVIEWING AND RECOMMENDING FOR THE EXECUTIVE COMMITTEE'S APPROVAL THE JOB DESCRIPTIONS FOR SENIOR STAFF POSITIONS; (G) ASSISTING MANAGEMENT IN THE ATTRACTION, DEVELOPMENT AND RETENTION OF TOP TALENT; (H) REVIEWING THE EVALUATION OF SENIOR STAFF BY THE CHIEF EXECUTIVE OFFICER AND MAKING RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE AS APPROPRIATE; (I) MAKING RECOMMENDATIONS TO THE EXECUTIVE COMMITTEE CONCERNING THE CHIEF EXECUTIVE OFFICER'S ANNUAL COMPENSATION AND BENEFITS; (J) APPROVING THE CHIEF EXECUTIVE OFFICER'S RECOMMENDATIONS AND ADVISING THE EXECUTIVE COMMITTEE OF SUCH CONCERNING ANNUAL COMPENSATION AND BENEFITS FOR SENIOR MANAGEMENT (INCLUDING NEW HIRES); (K) PROVIDING GUIDANCE TO THE EXECUTIVE COMMITTEE AND THE AUDIT AND FINANCE COMMITTEE WITH REGARD TO OVERALL COMPENSATION AND BENEFIT POLICIES AND (L) ASSISTING IN THE DEVELOPMENT AND RECOMMENDATION TO THE BOARD OF A COMPREHENSIVE SUCCESSION PLAN. SUBJECT TO THE PROVISIONS OF THIS SECTION 5.6, THE HUMAN RESOURCES COMMITTEE SHALL HAVE SUCH ADDITIONAL PURPOSE, MEMBERSHIP, GENERAL AND SPECIFIC FUNCTIONS AND RESPONSIBILITIES AS ARE PROVIDED FOR IN ANY COMMITTEE CHARTER OF THE HUMAN RESOURCES COMMITTEE APPROVED BY THE ENTIRE BOARD. B. OFFICERS OR KEY EMPLOYEES: OFFICERS OF THE COMPANY, ACCORDING TO THE BY-LAWS, ARE: (I) CHAIR OF THE BOARD - NO COMPENSATION PROVIDED (I) CHIEF EXECUTIVE OFFICER (III) CHIEF OPERATING OFFICER (IV) TREASURER (CHIEF FINANCIAL OFFICER) (V) SECRETARY (SENIOR IN-HOUSE COUNSEL). KEY EMPLOYEES ARE: CHIEF SCIENTIFIC OFFICER THESE PERSONS USE THE SAME PROCESS FOR ELECTION BY THE HUMAN RESOURCES COMMITTEE AS DESCRIBED ABOVE FOR ELECTING THE CEO, EXECUTIVE DIRECTOR OR TOP MANAGEMENT OFFICIAL.
FORM 990, PART VI, SECTION C, LINE 19YES DOCUMENTS ARE AVAILABLE TO THE PUBLIC: GOVERNING DOCUMENT - UPON REQUEST CONFLICT OF INTEREST POLICY - UPON REQUEST FINANCIAL STATEMENTS - AVAILABLE ON WEBSITE
CHANGES IN NET ASSETS OR FUND BALANCES:FORM 990, PART XI, LINE 5:NET UNREALIZED GAINS ON INVESTMENTS: 58,346.
FORM 990, PART XII, LINE 2CTHE PROCESS HAS NOT CHANGED

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII

Name Of Disregarded Entity NameOfDisregardedEntity

FieldValueIRS element (for citing)
Business Name Line1MULTIPLE MYELOMA RESEARCH CONSORTIUM INCBusinessNameLine1

Address US AddressUS

FieldValueIRS element (for citing)
Address Line1383 MAIN AVENUE 5TH FLOORAddressLine1
CityNORWALKCity
StateCTState
ZIP Code06851ZIPCode
FieldValueIRS element (for citing)
EIN811640775EIN
Primary ActivitiesTO ACCELERATE DRUG DEVELOPMENT FOR MULTIPLE MYELOMA &IMPROVE PATIENT OUTCOMEPrimaryActivities
Legal Domicile StateCTLegalDomicileState
Exempt Code Section509 (A) (3)ExemptCodeSection
Public Charity Status501 (C) (3)PublicCharityStatus

Direct Controlling Entity Name DirectControllingEntityName

FieldValueIRS element (for citing)
Business Name Line1THE MULTIPLE MYELOMA RESEARCH FOUNDATION INCBusinessNameLine1
FieldValueIRS element (for citing)
Controlled Org0ControlledOrg
FieldValueIRS element (for citing)
Receipt Of Int Ann Rents Royalties0ReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other Org1GiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other Org0GiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other Org0LoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other Org0LoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other Org0SaleOfAssetsToOtherOrg
Purchase Of Assets From Other Org0PurchaseOfAssetsFromOtherOrg
Exchange Of Assets0ExchangeOfAssets
Rental Of Facilities To Other Orgs0RentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other Orgs0RentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other Orgs0PerformOfServicesForOtherOrgs
Perform Of Services By Other Orgs0PerformOfServicesByOtherOrgs
Sharing Of Facilities1SharingOfFacilities
Sharing Of Paid Employees1SharingOfPaidEmployees
Reimbursement Paid To Other Org0ReimbursementPaidToOtherOrg
Reimbursement Paid By Other Org0ReimbursementPaidByOtherOrg
Other Transfer To Other Org0OtherTransferToOtherOrg
Other Transfer From Other Org0OtherTransferFromOtherOrg

Transactions Related Orgs Table TransactionsRelatedOrgsTable (3 entries)

Transaction TypeTransactionTypeAmount InvolvedAmountInvolved
MULTIPLE MYELOMA RESEARCH CONSORTIUM
B4145000
MULTIPLE MYELOMA RESEARCH CONSORTIUM
M160097
MULTIPLE MYELOMA RESEARCH CONSORTIUM
N674404

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.